ArticleCurrent health sciences journal
Biosafety and Selective Cytotoxicity of Kojic and Ellagic Acids in Salivary Gland Carcinoma: A Preclinical Perspective.
Article in Current health sciences journal. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
7 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Salivary gland carcinomas (SGCs) are rare, aggressive tumors with high histopathological diversity and resistance to conventional therapies. The need for novel therapeutic approaches has drawn attention to natural compounds with antitumor potential. Objective: This study aims to investigate the in vitro and in ovo cytotoxic and safety profiles of two natural agents, kojic acid (KA) and ellagic acid (EA), on human submandibular salivary gland carcinoma (A253) cells and human immortalized keratinocytes (HaCaT), as well as to assess their irritant potential via the HET-CAM assay. The cytotoxicity and morphological changes of A253 and HaCaT cells were evaluated using the MTT assay and brightfield microscopy. The HET-CAM assay was applied to evaluate the irritant effects of the compounds in ovo. Both KA and EA reduced A253 cell viability in a dose-dependent manner, with the highest cytotoxicity observed at 100 µM. In contrast, HaCaT cells maintained high viability and exhibited no notable morphological alterations post-treatment, supporting the selectivity of the compounds. HET-CAM scores for both KA and EA fell within the non-irritant range (IS=0.07), further confirming their biosafety. KA and EA exhibit promising antitumor activity against A253 salivary gland carcinoma cells, with minimal toxicity toward normal epithelial cells and no significant irritation potential. These findings justify further investigation of these compounds for their potential use as adjuvant agents in the treatment of salivary gland carcinoma (SGC).
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.